UK’s NICE Proposes Coverage For Troubled Sanofi Obesity Drug Rimonabant
This article was originally published in The Pink Sheet Daily
Executive Summary
British agency recommends CB-1 receptor antagonist as adjunct to diet and exercise for obese adults intolerant of Xenical, Meridia.
You may also be interested in...
Suicide Associated With Sanofi-Aventis’ Acomplia, U.K. Agency Says
One suicide and 48 suicidal ideation cases reported following treatment with Acomplia between June 2006 and May 9.
Suicide Associated With Sanofi-Aventis’ Acomplia, U.K. Agency Says
One suicide and 48 suicidal ideation cases reported following treatment with Acomplia between June 2006 and May 9.
Rimonabant Meta-Analysis Reveals Increased Risk Of Psychiatric Events – The Lancet
Study introduces nothing new about the obesity drug that has not been discussed with regulatory authorities, Sanofi-Aventis responds to “The Pink Sheet” DAILY.